NASDAQ:IBRX ImmunityBio Q2 2026 Earnings Report $7.91 +0.19 (+2.46%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$7.94 +0.03 (+0.39%) As of 09/11/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ImmunityBio EPS ResultsActual EPS-$0.22Consensus EPS -$0.08Beat/MissMissed by -$0.14One Year Ago EPSN/AImmunityBio Revenue ResultsActual Revenue$51.24 millionExpected Revenue$49.70 millionBeat/MissBeat by +$1.54 millionYoY Revenue GrowthN/AImmunityBio Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time7:30AM ETUpcoming EarningsImmunityBio's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ImmunityBio Earnings HeadlinesIBRX stock eyes worst week since July: New patent eyes broader Anktiva use ahead of lung cancer conferenceSeptember 11 at 9:40 AM | msn.comSLS, IBRX in focus: Canadian insurance giant Manulife’s unit raises stakes ahead of key cancer catalystsSeptember 10 at 3:55 AM | msn.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 12 at 1:00 AM | Investors Alley (Ad)ImmunityBio (IBRX) Gets a Buy from Piper SandlerSeptember 9 at 10:55 PM | theglobeandmail.comImmunityBio: None Of The Moonshots Is Priced InSeptember 3, 2026 | seekingalpha.comSLS, IBRX stocks post August gains: Eli Lilly’s latest $2.9B deal has retail traders bracing for an 'M&A rampage'September 1, 2026 | msn.comSee More ImmunityBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email. Email Address About ImmunityBioImmunityBio (NASDAQ:IBRX) is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings. ImmunityBio’s development programs have included cancer vaccines, engineered cell therapies and combination regimens intended to address solid tumors and other serious diseases. The company conducts clinical development and commercial activities primarily in the United States, while its therapies have been studied through international research programs. Patrick Soon-Shiong, M.D., is the company’s founder and executive chairman and has served as its chief executive officer.View ImmunityBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
